BR9814282A - "compositions and methods for treating attention deficit disorder and attention deficit / hyperactivity disorder with methylphenidate" - Google Patents

"compositions and methods for treating attention deficit disorder and attention deficit / hyperactivity disorder with methylphenidate"

Info

Publication number
BR9814282A
BR9814282A BR9814282-8A BR9814282A BR9814282A BR 9814282 A BR9814282 A BR 9814282A BR 9814282 A BR9814282 A BR 9814282A BR 9814282 A BR9814282 A BR 9814282A
Authority
BR
Brazil
Prior art keywords
attention deficit
disorder
methylphenidate
compositions
methods
Prior art date
Application number
BR9814282-8A
Other languages
Portuguese (pt)
Inventor
Juan Mantelle
Terese A Dixon
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Publication of BR9814282A publication Critical patent/BR9814282A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE DISTúRBIO DE DéFICIT DE ATENçãO E DISTúRBIO DE DéFICIT/HIPERATIVIDADE DE ATENçãO COM METILFENIDATO"<D>. A invenção refere-se a um método de tratamento de Distúrbio de Déficit de Atenção (ADD) e Distúrbio de Déficit de Atenção/Hiperatividade (ADHD) e a composições para aplicação tópica de metilfenidato compreendendo metilfenidato em um sistema finito flexível, em que o metilfenidato está presente em uma proporção suficiente para atingir substancialmente uma cinética de ordem zero para transferência para a pele ou mucosa de um paciente carente dele por um período de pelo menos 10 horas.Invention Patent: <B> "COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT / HYPERACTIVITY DISORDER WITH METHYLENIDATE" <D>. The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit / Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible finite system, in which the methylphenidate it is present in a proportion sufficient to achieve substantially zero order kinetics for transfer to the skin or mucosa of a patient in need of it for a period of at least 10 hours.

BR9814282-8A 1997-12-15 1998-12-14 "compositions and methods for treating attention deficit disorder and attention deficit / hyperactivity disorder with methylphenidate" BR9814282A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
PCT/US1998/026560 WO1999030694A2 (en) 1997-12-15 1998-12-14 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
BR9814282A true BR9814282A (en) 2000-10-03

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814282-8A BR9814282A (en) 1997-12-15 1998-12-14 "compositions and methods for treating attention deficit disorder and attention deficit / hyperactivity disorder with methylphenidate"

Country Status (28)

Country Link
US (2) US6210705B1 (en)
EP (2) EP1037615B1 (en)
JP (3) JP4316800B2 (en)
KR (1) KR100633348B1 (en)
CN (1) CN1368876A (en)
AR (1) AR014062A1 (en)
AT (1) ATE260652T1 (en)
AU (1) AU752027B2 (en)
BR (1) BR9814282A (en)
CA (1) CA2315237C (en)
CZ (2) CZ300535B6 (en)
DE (1) DE69822199T2 (en)
DK (1) DK1037615T3 (en)
ES (2) ES2219926T3 (en)
HK (2) HK1049447A1 (en)
HU (1) HU226615B1 (en)
IL (1) IL136760A0 (en)
LV (1) LV12558B (en)
NO (1) NO329974B1 (en)
NZ (1) NZ505689A (en)
PE (1) PE20000120A1 (en)
PL (1) PL195315B1 (en)
PT (1) PT1037615E (en)
RU (1) RU2233156C2 (en)
SI (1) SI20360B (en)
TR (1) TR200001736T2 (en)
TW (2) TWI244396B (en)
WO (1) WO1999030694A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (en) * 1999-11-15 2003-03-31 Novartis Ag SILILATED HETEROCICLIC COMPOUNDS, PROCEDURE FOR THE PREPARATION OF THESE AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
ATE252903T1 (en) * 1999-12-17 2003-11-15 Celltech Pharma Europ Ltd MEDICINAL PRODUCTS FOR THE TREATMENT OF CONVULSIVE CONDITIONS
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (en) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive
CN1250206C (en) * 2001-03-07 2006-04-12 久光制药株式会社 Adhesive patch
FR2822049B1 (en) * 2001-03-13 2003-08-01 Dbv Medica 1 PATCH INTENDED IN PARTICULAR TO DETECT THE STATE OF SENSITIZATION OF A SUBJECT TO AN ALLERGEN, METHOD OF MANUFACTURING AND USE
WO2002074286A1 (en) * 2001-03-16 2002-09-26 Alza Corporation Transdermal patch for administering fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE10141652B4 (en) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups and its use
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (en) * 2002-08-28 2009-10-28 久光製薬株式会社 Patch
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
UA84303C2 (en) * 2003-10-28 2008-10-10 Новен Фармасьютикалз, Инк. Transdermal drug delivery system
WO2006078887A2 (en) 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and uses of them
WO2006078984A2 (en) * 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Uses of methylphenidate derivatives
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
US8715723B2 (en) * 2006-02-27 2014-05-06 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
MY144201A (en) * 2006-05-01 2011-08-15 Colgate Palmolive Co Oral care composition with silicone composite
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
RU2499583C2 (en) * 2007-10-15 2013-11-27 Алза Корпорейшн Replaced transdermal of administration of phentanyl
FR2924350B1 (en) * 2007-12-03 2010-08-13 Dbv Tech METHOD AND COMPOSITIONS FOR SKIN VACCINATION
FR2924349B1 (en) * 2007-12-03 2010-01-01 Dbv Tech ALLERGEN DISENSIBILITY METHOD
JP2011506318A (en) 2007-12-06 2011-03-03 デュレクト コーポレーション Oral pharmaceutical formulation
CN102006893A (en) * 2007-12-31 2011-04-06 阿克拉伦特公司 Mucosal tissue dressing and method of use
FR2926466B1 (en) * 2008-01-23 2010-11-12 Dbv Tech METHOD FOR MANUFACTURING PATCHES BY ELECTROSPRAY
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (en) * 2008-12-11 2013-02-27 日東電工株式会社 Methylphenidate patch preparation
US9228779B2 (en) * 2009-06-05 2016-01-05 Megtec Systems, Inc. Infrared float bar
EP2364695A1 (en) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidate patch preparation
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
KR101616111B1 (en) 2011-07-28 2016-04-27 켐팜 인코포레이티드 Methylphenidate-prodrugs, processes of making and using the same
AR092999A1 (en) 2012-10-15 2015-05-13 Noven Pharma COMPOSITIONS AND METHODS FOR THE TRANSDERMIC ADMINISTRATION OF METHYLPHENIDATE
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014106014A1 (en) 2012-12-28 2014-07-03 Noven Pharmaceuticals, Inc Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
JP6359032B2 (en) 2012-12-28 2018-07-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド Multi-polymer composition for transdermal drug delivery
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11337936B2 (en) 2013-03-14 2022-05-24 Noven Pharmaceuticals, Inc. Amphetamine transdermal compositions with acrylic block copolymer
AR095259A1 (en) 2013-03-15 2015-09-30 Noven Pharma COMPOSITIONS AND METHODS FOR THE TRANSDERMAL ADMINISTRATION OF TERTIARY AMINE DRUGS
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AR095260A1 (en) 2013-03-15 2015-09-30 Noven Pharma COMPOSITIONS OF STABLE TRANSDERMAL AMPHETAMINS AND MANUFACTURING METHODS
SI3087984T1 (en) 2013-12-25 2021-08-31 Fujimoto Co., Ltd. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
CN106511264A (en) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 Methylphenidate hydrochloride oral solution and preparation method thereof
NZ754751A (en) 2016-12-11 2022-05-27 Kempharm Inc Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3598982A1 (en) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP2693212B2 (en) * 1989-03-28 1997-12-24 日東電工株式会社 Tape preparation for disease treatment
AU1992592A (en) * 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
AU4673993A (en) 1992-07-28 1994-02-14 Procter & Gamble Company, The Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
CH691209A5 (en) 1993-09-06 2001-05-15 Scherrer Inst Paul Manufacturing process for a polymer electrolyte and electrochemical cell with this polymer electrolyte.
EP0689920B1 (en) 1994-06-29 1999-10-13 Hennecke GmbH Method and apparatus for the continuous production of foam plastic blocks or sheets
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1998039042A1 (en) 1997-03-07 1998-09-11 Jackson Richard R Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
US6684641B2 (en) 1999-12-15 2004-02-03 Osaka Gas Co., Ltd. Fluid distributor, burner device, gas turbine engine, and cogeneration system

Also Published As

Publication number Publication date
KR20010033114A (en) 2001-04-25
EP1037615B1 (en) 2004-03-03
AR014062A1 (en) 2001-01-31
CN1368876A (en) 2002-09-11
ES2452517T3 (en) 2014-04-01
AU1824999A (en) 1999-07-05
IL136760A0 (en) 2001-06-14
NZ505689A (en) 2003-01-31
LV12558B (en) 2001-03-20
CZ300535B6 (en) 2009-06-10
PL195315B1 (en) 2007-08-31
PE20000120A1 (en) 2000-02-19
NO20003096D0 (en) 2000-06-15
NO329974B1 (en) 2011-01-31
WO1999030694A2 (en) 1999-06-24
JP2002510600A (en) 2002-04-09
CA2315237A1 (en) 1999-06-24
AU752027B2 (en) 2002-09-05
TWI242452B (en) 2005-11-01
PT1037615E (en) 2004-07-30
PL341596A1 (en) 2001-04-23
TW200406231A (en) 2004-05-01
HK1049447A1 (en) 2003-05-16
JP2009073856A (en) 2009-04-09
SI20360B (en) 2008-06-30
DE69822199D1 (en) 2004-04-08
KR100633348B1 (en) 2006-10-16
CZ305817B6 (en) 2016-03-23
EP2314288A1 (en) 2011-04-27
JP4316800B2 (en) 2009-08-19
ATE260652T1 (en) 2004-03-15
ES2219926T3 (en) 2004-12-01
LV12558A (en) 2000-11-20
US6348211B1 (en) 2002-02-19
DE69822199T2 (en) 2005-02-17
EP1037615A2 (en) 2000-09-27
EP2314288B1 (en) 2013-12-11
DK1037615T3 (en) 2004-07-12
RU2233156C2 (en) 2004-07-27
CA2315237C (en) 2009-12-01
HU226615B1 (en) 2009-04-28
HUP0004539A3 (en) 2006-06-28
WO1999030694A3 (en) 1999-08-19
US6210705B1 (en) 2001-04-03
HK1156872A1 (en) 2012-06-22
CZ2009132A3 (en) 2016-03-23
JP2013056944A (en) 2013-03-28
HUP0004539A2 (en) 2001-06-28
TWI244396B (en) 2005-12-01
NO20003096L (en) 2000-08-15
CZ20002209A3 (en) 2000-11-15
TR200001736T2 (en) 2001-01-22
SI20360A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
BR9814282A (en) &#34;compositions and methods for treating attention deficit disorder and attention deficit / hyperactivity disorder with methylphenidate&#34;
BR0213540A (en) Compounds, method for treating a patient&#39;s illness or disorder and a pharmaceutical composition comprising them
FI964284A0 (en) Polymorphism of apolipoprotein E and treatment of Alzheimer&#39;s disease
DE69535540D1 (en) COMPOSITION CONTAINING NUCLEIC ACIDS AND CATIONIC POLYMERS, PREPARATION AND USE
BR0312421A (en) Use of cept inhibitors and optionally hmg coa reductase inhibitors and / or antihypertensive agents
BR9812965A (en) Methods for treating hypercoagulable states or acquired protein deficiency
BRPI0415397A (en) methods and reagents for the treatment of immunoinflammatory disorders
BR9814984A (en) Processes to treat physical conditions resulting from postmenopausal estrogen decline in a postmenopausal patient and to reduce the risk of osteoporotic bone fractures in a patient, and, set for use by a consumer tormented with, or susceptible to, resulting physical conditions of postmenopausal estrogen decline
BR0315598A (en) Neutralizing antibodies to gdf-8 and their uses
BR9913585A (en) Formulation of stable liquid pharmaceutical botulinum toxin, method of treating a patient in need of inhibition of cholinergic entry into a selected muscle, muscle group, gland or organ, and use of a formulation of stable liquid botulinum toxin
DE69527987D1 (en) FORMULATIONS AND METHOD FOR REDUCING SKIN IRRITATION
BRPI0411319A (en) therapeutically active compounds and their use
PT808898E (en) REAGENT AND METHOD FOR INHIBITING N-RAS EXPRESSION
BR0003800A (en) Process for fractioning polymer dispersions
ATE356995T1 (en) METHOD FOR IDENTIFYING AGENTS FOR TREATING DIABETES
BR9813996A (en) 2-arylbenzo [b] thiophenes useful for the treatment of estrogen deprivation syndrome
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
HUP0100066A2 (en) Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
BR9708864A (en) Compound pharmaceutical composition and process for the treatment or prevention of a bacterial infection in a mammalian patient
BR9300651A (en) PROCESS TO DETERMINE THE PRESENCE AND / OR CONCENTRATION OF A POLYMER FOR WATER TREATMENT IN A WATER SAMPLE, HYBRIDOMA AND COMPOSITION
DE50014268D1 (en) COMPOSITION, CONTAINING BACTERIAL ANTIGENE, FOR PREVENTING AND TREATING ALLERGIC DISEASES
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
BR9811643A (en) Chemical bone supplementation
BR9510015A (en) Compound pharmaceutical composition and process for the treatment of infectious diseases in human or veterinary therapy
BR9908443A (en) Human spinal cord cell lines and methods for using them

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
HKFN Application deemed withdrawn (deleted)
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/70, A61K 31/4458, A61P 25/26

Ipc: A61K 9/70 (2008.01), A61K 31/4458 (2008.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]